cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Opko Health Inc
29 own
40 watching
Current Price
$1.45
$-0.02
(-1.36%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,087.91M
52-Week High
52-Week High
1.76000
52-Week Low
52-Week Low
0.85000002
Average Volume
Average Volume
2.02M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
34.9406
iconMarket Capitalization1,087.91M
icon52-Week High1.76000
icon52-Week Low0.85000002
iconAverage Volume2.02M
iconDividend Yield--
iconP/E Ratio34.9406
What does the Opko Health Inc do?
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.
Read More
How much money does Opko Health Inc make?
News & Events about Opko Health Inc.
PR Newswire
1 year ago
Thinking about buying stock in Marinus Pharmaceuticals, OPKO Health, Xponential Fitness, Plug Power, or Asetek A/S? Thinking about buying stock in Marinus Pharmaceuticals, OPKO Health, Xponential Fitness, Plug Power, or Asetek A/S? PR Newswire NEW YORK, June 28, 2023 NEW YORK, June 28, 2023...
Globe Newswire
1 year ago
MIAMI, March 09, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that it will hold an R&D Day event on March 20, 2023 beginning at 4:00 p.m. Eastern time. The two-hour virtual event will provide an opportunity to hear from OPKO executives about the ModeX Therapeutics ...
Globe Newswire
1 year ago
MDX-2201 leverages ModeXs innovative biologics platform to target multiple Epstein-Barr virus (EBV) proteinsEBV is the leading cause of infectious mononucleosis and is also associated with some specific types of cancer MIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today ...
Globe Newswire
1 year ago
MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, February 23, 2023. OPKOs senior management will provide a business update ...
PR Newswire
1 year ago
BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings PR Newswire ELMWOOD PARK, N.J., Feb. 9, 2023 CINtecPLUS Cytology offered as a reflex...
Frequently Asked Questions
Frequently Asked Questions
What is Opko Health Inc share price today?
plus_minus_icon
Can Indians buy Opko Health Inc shares?
plus_minus_icon
How can I buy Opko Health Inc shares from India?
plus_minus_icon
Can Fractional shares of Opko Health Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Opko Health Inc stocks?
plus_minus_icon
What is today’s traded volume of Opko Health Inc?
plus_minus_icon
What is today’s market capitalisation of Opko Health Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Opko Health Inc?
plus_minus_icon
What percentage is Opko Health Inc down from its 52-Week High?
plus_minus_icon
What percentage is Opko Health Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.45
$-0.02
(-1.36%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
LivaNova PLC
LivaNova PLC
$46.65
$0.34 (0.73 %)
NovoCure Limited
NovoCure Limited
$29.99
$0.19 (0.64 %)
Xencor Inc
Xencor Inc
$23.79
$0.81 (3.52 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$326.16
$-2.35 (-0.72 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
LivaNova PLC
LivaNova PLC
$46.65
$0.34 (0.73 %)
NovoCure Limited
NovoCure Limited
$29.99
$0.19 (0.64 %)
Xencor Inc
Xencor Inc
$23.79
$0.81 (3.52 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$326.16
$-2.35 (-0.72 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00